Stock listing
TSXV:MRVL Marvel Biosciences Corp Stock
Home listing (TSXV) of Marvel Biosciences Corp
Follow Marvel Biosciences Corp into a list and get an email when it puts out news.
Share price · TSXV:MRVL
$0.115 CAD 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.115 – $0.115 CADNov 20, 2026
- Volume
- 13,444 sharesNov 20, 2026
- Market cap
- $8.47M CADAt the close on Nov 20, 2026 · price × 73.68M shares outstanding
- 52-week range
- $0.095 – $0.250 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10,760 CADMedian day 30,176 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:MRVL · Home | $0.115 CAD | 0.000 (0.0%) | 13,444 | $0.115 | $0.115 | $0.115 | $0.115 | Close on Nov 20, 2026 |
| OTC:MBCOF | $0.08 USD | 0.00 (0.0%) | 16,231 | $0.08 | $0.08 | $0.08 | $0.08 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSXV:MRVL · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.115 | 0.000 | 0.0% | $0.115 | $0.115 | $0.115 | 13,444 | |
| $0.115 | -0.015 | -11.5% | $0.130 | $0.130 | $0.115 | 29,518 | |
| $0.130 | 0.000 | 0.0% | $0.130 | $0.130 | $0.125 | 15,085 | |
| $0.130 | 0.000 | 0.0% | $0.135 | $0.135 | $0.130 | 24,370 | |
| $0.130 | +0.005 | +4.0% | $0.130 | $0.130 | $0.130 | 12,731 | |
| $0.125 | +0.010 | +8.7% | $0.130 | $0.130 | $0.125 | 12,149 | |
| $0.115 | -0.005 | -4.2% | $0.125 | $0.130 | $0.115 | 75,200 | |
| $0.120 | 0.000 | 0.0% | $0.115 | $0.120 | $0.115 | 19,500 | |
| $0.120 | 0.000 | 0.0% | $0.115 | $0.120 | $0.095 | 79,606 | |
| $0.120 | +0.005 | +4.3% | $0.120 | $0.120 | $0.110 | 26,590 | |
| $0.115 | +0.005 | +4.5% | $0.110 | $0.120 | $0.100 | 252,068 | |
| $0.110 | -0.005 | -4.3% | $0.115 | $0.115 | $0.110 | 44,806 | |
| $0.115 | -0.005 | -4.2% | $0.115 | $0.120 | $0.115 | 31,666 | |
| $0.120 | 0.000 | 0.0% | $0.120 | $0.120 | $0.120 | 4,134 | |
| $0.120 | 0.000 | 0.0% | $0.120 | $0.120 | $0.120 | 5,000 | |
| $0.120 | 0.000 | 0.0% | $0.125 | $0.125 | $0.120 | 5,569 | |
| $0.120 | 0.000 | 0.0% | $0.125 | $0.125 | $0.120 | 29,000 | |
| $0.120 | -0.005 | -4.0% | $0.120 | $0.120 | $0.120 | 85,605 | |
| $0.125 | +0.010 | +8.7% | $0.120 | $0.125 | $0.115 | 58,559 | |
| $0.115 | 0.000 | 0.0% | $0.120 | $0.120 | $0.115 | 30,833 | |
| $0.115 | -0.005 | -4.2% | $0.125 | $0.125 | $0.115 | 111,000 | |
| $0.120 | 0.000 | 0.0% | $0.120 | $0.120 | $0.120 | 2,109 | |
| $0.120 | +0.025 | +26.3% | $0.095 | $0.120 | $0.095 | 280,267 | |
| $0.095 | -0.005 | -5.0% | $0.100 | $0.100 | $0.095 | 27,525 | |
| $0.100 | 0.000 | 0.0% | $0.105 | $0.110 | $0.100 | 58,039 | |
| $0.100 | -0.010 | -9.1% | $0.105 | $0.105 | $0.100 | 118,800 | |
| $0.110 | 0.000 | 0.0% | $0.110 | $0.110 | $0.105 | 33,500 | |
| $0.110 | -0.005 | -4.3% | $0.110 | $0.110 | $0.110 | 53,258 | |
| $0.115 | 0.000 | 0.0% | $0.110 | $0.120 | $0.110 | 75,000 | |
| $0.115 | +0.010 | +9.5% | $0.105 | $0.115 | $0.105 | 148,996 | |
| $0.105 | -0.005 | -4.5% | $0.120 | $0.120 | $0.105 | 88,392 | |
| $0.110 | 0.000 | 0.0% | $0.110 | $0.120 | $0.110 | 177,779 | |
| $0.110 | -0.010 | -8.3% | $0.120 | $0.120 | $0.105 | 226,209 | |
| $0.120 | -0.030 | -20.0% | $0.150 | $0.150 | $0.120 | 474,666 | |
| $0.150 | -0.005 | -3.2% | $0.155 | $0.155 | $0.150 | 14,358 | |
| $0.155 | 0.000 | 0.0% | $0.155 | $0.160 | $0.155 | 27,118 | |
| $0.155 | +0.005 | +3.3% | $0.145 | $0.155 | $0.145 | 176,922 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.145 | 21,841 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.150 | 3,500 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.150 | 5,400 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.145 | 18,200 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.120 | 51,805 | |
| $0.150 | +0.005 | +3.4% | $0.145 | $0.150 | $0.145 | 6,515 | |
| $0.145 | 0.000 | 0.0% | $0.145 | $0.145 | $0.145 | 15,578 | |
| $0.145 | -0.005 | -3.3% | $0.145 | $0.150 | $0.145 | 18,001 | |
| $0.150 | 0.000 | 0.0% | $0.145 | $0.150 | $0.145 | 10,066 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.145 | 715,100 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.130 | 730,716 | |
| $0.150 | +0.010 | +7.1% | $0.150 | $0.150 | $0.125 | 57,296 | |
| $0.140 | 0.000 | 0.0% | $0.140 | $0.140 | $0.140 | 1,600 | |
| $0.140 | 0.000 | 0.0% | $0.145 | $0.145 | $0.140 | 17,900 | |
| $0.140 | -0.010 | -6.7% | $0.150 | $0.155 | $0.130 | 149,374 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.150 | 16,793 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.155 | $0.140 | 43,596 | |
| $0.150 | -0.005 | -3.2% | $0.150 | $0.150 | $0.150 | 17,001 | |
| $0.155 | +0.005 | +3.3% | $0.150 | $0.155 | $0.145 | 36,014 | |
| $0.150 | -0.005 | -3.2% | $0.150 | $0.150 | $0.150 | 12,637 | |
| $0.155 | +0.005 | +3.3% | $0.150 | $0.155 | $0.145 | 82,926 | |
| $0.150 | 0.000 | 0.0% | $0.155 | $0.155 | $0.145 | 71,600 | |
| $0.150 | 0.000 | 0.0% | $0.145 | $0.155 | $0.145 | 70,333 | |
| $0.150 | -0.005 | -3.2% | $0.155 | $0.155 | $0.150 | 23,927 | |
| $0.155 | +0.005 | +3.3% | $0.160 | $0.160 | $0.155 | 19,610 | |
| $0.150 | -0.005 | -3.2% | $0.165 | $0.165 | $0.150 | 18,112 | |
| $0.155 | -0.010 | -6.1% | $0.155 | $0.165 | $0.155 | 44,356 |
- Ticker
- TSXV:MRVL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TSXV
- Currency
- CAD
What changed lately
Latest news release · Nov 18, 2026
Marvel Biosciences Announces Grant of Deferred Share Units
Latest deck · February 2026
Investor Presentation (February 2026)
Investor deck · 15 slides
Latest news
Marvel Biosciences Announces Grant of Deferred Share Units
Nov 18, 2026
Closed $0.115 (0.0%) on Nov 20, 2026
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours
Nov 10, 2026
Closed $0.12 (0.0%) on Nov 10, 2026
CEO.CA's Inside the Boardroom: No Approved Drug Does What Marvel's Lead Candidate Can Do for Autism
Oct 21, 2026
Closed $0.12 (0.0%) on Oct 21, 2026
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
Oct 19, 2026
Closed $0.095 (-5.0%) on Oct 19, 2026
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Oct 8, 2026
Closed $0.115 (+9.5%) on Oct 8, 2026
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
Oct 6, 2026
Closed $0.11 (0.0%) on Oct 6, 2026
Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
Sep 29, 2026
Closed $0.155 (0.0%) on Sep 30, 2026
Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
Sep 17, 2026
Closed $0.145 (0.0%) on Sep 18, 2026
Marvel Biosciences Announces Extension to Closing Date of Private Placement
Sep 9, 2026
Closed $0.14 (0.0%) on Sep 9, 2026
Marvel Biosciences Expands Private Placement to Quebec
Aug 19, 2026
Closed $0.165 (+3.1%) on Aug 19, 2026
Marvel Biosciences Corp on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 101 in all · newest Nov 18, 2026 · oldest 2021
- Decks
- 5 decks · latest February 2026
Where Marvel Biosciences Corp is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:MRVL · Home listing · This page | TSXV | Canada | CAD |
| Cboe Canada:MRVL | Cboe Canada | Canada | CAD |
| OTC:MBCOF | OTC | United States | USD |
Valuation
Statements: 4 quarters to Apr 30, 2026 · price Nov 20, 2026
- Enterprise value
- $8.66M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.91
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Marvel Biosciences Corp · TSXV:MRVL | US$5.91M | US$6.04M | n/a | n/a | n/a | n/a | n/a | n/a | 0.91 |
| Kyntra Bio, Inc. · NASDAQ:KYNB | US$6.32M | −US$33.97M | n/a | −6.4× | n/a | n/a | −326.0% | n/a | 1.58 |
| Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP | US$6.30M | −US$3.35M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| TrivarX Limited · ASX:TRI | US$6.11M | US$4.58M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| Enveric Biosciences, Inc. · NASDAQ:ENVB | US$6.04M | US$429,455 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 0.76 |
| Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDB | US$6.03M | US$6.03M | n/a | 314× | n/a | 5.4× | n/a | 0.0× | n/a |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Exicure, Inc. · NASDAQ:XCUR | US$5.89M | US$4.67M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.49 |
| Tempest Therapeutics, Inc. · NASDAQ:TPST | US$5.74M | US$4.84M | n/a | n/a | n/a | n/a | n/a | n/a | 1.09 |
| Oncotelic Therapeutics Inc · OTC:OTLC | US$5.58M | US$5.52M | 0.0× | n/a | n/a | 0.0× | n/a | 0.0× | 0.07 |
| Median of the others | US$5.99M | US$4.62M | 0.0× | 68.2× | 1.3× | −326.0% | 0.0× | 0.93 |
Team and board
Officers
| Officer | Role |
|---|---|
| J. Roderick Matheson | Chief Executive Officer and Director |
| Harry Nijjar | Chief Financial Officer, CPA, CMA |
| Mark Williams | President, Chief Science Officer and Director |
Board
| Director | Role |
|---|---|
| Babak Pedram | Director |
| J. Roderick Matheson | Chief Executive Officer and Director |
| Mark Williams | President, Chief Science Officer and Director |
| Neil A. Johnson | Director |
| Randall Smallbone | Director |
Events
- Next results
- Nov 26, 2026 (expected)
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2026) | Investor deck | 15 slides | February 2026 |
| Investor Presentation (December 2024) | Investor deck | 18 slides | December 2024 |
| Investor Presentation (December 2024) | Investor deck | 19 slides | December 2024 |
| Investor Presentation (May 2023) | Investor deck | 29 slides | May 2023 |
| Investor Presentation (April 2022) | Investor deck | 31 slides | April 2022 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Closed: C$1.6M raised · C$0.15 a unit · 1 warrant at C$0.2 for 12 months · Raymond James Ltd. +5 Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Research Capital Corporation (finder), Acumen Capital Finance Partners Limited (finder), Hampton Securities (finder), Leede Financial Inc. (finder) Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital | Sep 29, 2026 | US$1.13M |
| Unsecured convertible debentures Closed: C$500,000 raised · C$0.17 · free to trade Aug 17, 2026 Use of proceeds: Drug formulation, toxicology studies and general working capital | Apr 17, 2026 | US$365,738 |
| Warrant exercise of common share purchase warrants Announced: Warrants at C$0.15 | Oct 3, 2025 | |
| Private placement of units Closed: C$1.02M raised · C$0.125 a unit · 1 warrant at C$0.175 for 24 months · Raymond James Ltd. +5 Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Acumen Capital Finance Partners Limited (finder), Wood Gundy (finder), Abinvest Corporation (finder), Abingdon Capital Corp. (finder) Use of proceeds: Drug formulation, toxicology studies and general working capital | May 12, 2025 | |
| Private placement of common shares Cancelled: C$1.94M–C$2.5M · C$0.15 a share · Abingdon Capital Dealers: Abingdon Capital (finder) Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital | May 2, 2025 | US$1.35M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 547.4K | 302.0K | 887.5K | 1.38M | 613.1K | 265.2K | |
| Gross profit | -547.4K | -302.0K | -887.5K | -1.38M | -613.1K | -265.2K | |
| Research and development | 547.4K | 302.0K | 887.5K | 1.38M | |||
| Selling, general and administrative | 920.8K | 913.4K | 1.41M | 1.17M | 1.25M | 1.02M | |
| Operating income | -1.25M | -1.27M | -2.25M | -2.55M | -1.10M | -954.8K | |
| Depreciation and amortization | 0 | 152 | 185 | 413 | 284 | ||
| EBITDA | -2.25M | -2.55M | -1.10M | -954.4K | |||
| Interest expense | 268.0K | 114.0K | 38.4K | 0 | 0 | 0 | 0 |
| Income before tax | -2.21M | -1.65M | -2.29M | -2.55M | -3.04M | -955.7K | |
| Income tax | -151.8K | -63.5K | |||||
| Net income | -2.21M | -1.65M | -2.29M | -2.55M | -3.04M | -955.7K | |
| Earnings per share, basic | -0.04 | -0.04 | -0.06 | -0.07 | -0.09 | -0.03 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 128.9K | 345.8K | 556.6K | 593.2K | 2.39M | 224.8K | |
| Receivables | 56.4K | 59.1K | 35.8K | ||||
| Current assets | 326.7K | 491.3K | 672.4K | 913.5K | 2.47M | 295.6K | 171 |
| Property, plant and equipment | 152 | 337 | 750 | ||||
| Total assets | 326.7K | 491.3K | 672.4K | 913.5K | 2.47M | 296.0K | |
| Accounts payable | 1.50M | 1.35M | 1.21M | 262.1K | 1.56K | 94.2K | 50.7K |
| Current liabilities | 4.33M | 3.32M | 1.39M | 718.0K | 112.5K | 177.2K | 209.3K |
| Long-term debt | 1.71M | 1.00M | |||||
| Total liabilities | 4.33M | 3.32M | 2.39M | 718.0K | 112.5K | 177.2K | |
| Shareholders' equity | -4.01M | -2.83M | -1.72M | 195.5K | 2.36M | 118.8K | |
| Shares outstanding | 53.0M | 44.8M | 39.8M | 37.1M | 32.6M | 32.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M | -538.5K | -157.4K |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | -1.03K |
| Free cash flow | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M | -538.5K | -158.4K |
| Cash from investing | 381.6K | 381.6K | -1.03K | ||||
| Cash from financing | 933.4K | 968.6K | 1.30M | 394.0K | 3.16M | 763.2K | 158.6K |
| Change in cash | -216.9K | -210.9K | -36.6K | -1.80M | 2.17M | 224.6K | 171 |
Cap table
Built by 6ix from Marvel Biosciences Corp’s releases · as of Sep 30, 2026
- Common shares
- 73,682,588
- Fully diluted
- 95,841,316
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 73,682,588 | Sep 29, 2026 |
| Warrants | 22,099,035 | Sep 30, 2026 |
| Options and RSUs | 59,693 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.20 · expire about Sep 2027 |
| Warrants · C$0.18 · expire about Mar 2027 |
| Broker warrants · expiry not stated |
| Broker warrants · C$0.20 · expiry not stated |
| Broker warrants · C$0.20 · expiry not stated |
| DSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Sep 29, 2026 | 73,682,588 |
| Apr 30, 2026 | 63,028,290 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mark Williams Other companies: TMX Group Ltd. (President and Chief Science Officer · Since at least Dec 22, 2025) | President, Chief Science Officer and Director · Since at least Oct 21, 2026 |
| Babak Pedram | Director · Since at least Nov 5, 2026 |
| Harry Nijjar | Chief Financial Officer, CPA, CMA · Since at least Nov 4, 2026 |
| J. Roderick Matheson | Chief Executive Officer and Director · Since at least Oct 19, 2026 |
| Neil A. Johnson | Director · Since at least Jan 7, 2025 |
| Randall Smallbone | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Marvel Biosciences Corp.